Literature DB >> 1972888

Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication.

L S Kucera1, E Leake, N Iyer, D Raben, Q N Myrvik.   

Abstract

Experiments were designed to determine whether HIV-1 and herpes simplex virus type 2 (HSV-2) coinfection leads to simultaneous replication of both viruses in the same human CD4+ cell (MT-4 cell line) and the possible effects of coinfection on infectious virus production. Results from transmission electron microscopy analysis revealed replication of typical HSV-2 nucleocapsids in the nucleus and budding of HIV-1 particles through the plasma membrane and through intracytoplasmic vacuoles containing enveloped HSV-2 particles in the same coinfected cell. Coinfection of HIV-1 persistently infected H9IIIB or promonocytic U1 cells with HSV-2 did not alter total production of infectious HSV-2 or the percentage of HSV-2 infectious centers compared with control H9 and U937 cells infected with HSV-2 alone. However, in coinfected promonocytic U1 cells HSV-2 induced infectious HIV-1 production measured by syncytial plaque assay. In summary, both HIV-1 and HSV-2 can coinfect and simultaneously replicate in the same human CD4+ cell. Interactions between HIV-1 and HSV-2 appear to be unidirectional, resulting in accelerated replication of HIV-1 as reported by Albrecht et al. (J Virol 1989;63:1861-1868), but not HSV-2 as shown by us.

Entities:  

Mesh:

Year:  1990        PMID: 1972888     DOI: 10.1089/aid.1990.6.641

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

Review 1.  Update in HIV medicine for the generalist.

Authors:  Amina A Chaudhry; Gail Berkenblit; Allen L Gifford; Joseph Cofrancesco; James Sosman; Lynn E Sullivan
Journal:  J Gen Intern Med       Date:  2010-12-08       Impact factor: 5.128

2.  Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?

Authors:  Darrell H S Tan; Rupert Kaul; Sharon Walsmley
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

4.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

5.  Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Authors:  Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Curr Trends Immunol       Date:  2012

6.  Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy.

Authors:  Jeffrey Thomas Schouten; Joshua T Schiffer
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

7.  Stepwise release of biologically active HMGB1 during HSV-2 infection.

Authors:  Chloé Borde; Stéphanie Barnay-Verdier; Claire Gaillard; Hakim Hocini; Vincent Maréchal; Joël Gozlan
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

8.  Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Beatriz Grinsztejn; Pedro Cahn; Sharon L Walmsley
Journal:  Trials       Date:  2010-11-24       Impact factor: 2.279

9.  A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Authors:  Federica Crostarosa; Meropi Aravantinou; Onome J Akpogheneta; Edith Jasny; Andrew Shaw; Jessica Kenney; Michael Piatak; Jeffrey D Lifson; Aaron Teitelbaum; Lieyu Hu; Anne Chudolij; Thomas M Zydowsky; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

10.  Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.

Authors:  Clare Tanton; Helen A Weiss; Mary Rusizoka; Jerome Legoff; John Changalucha; Kathy Baisley; Kokugonza Mugeye; Dean Everett; Laurent Belec; Tim C Clayton; David A Ross; Richard J Hayes; Deborah Watson-Jones
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.